Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Protara Therapeutics (TARA) Leases (2019 - 2026)

Protara Therapeutics' Leases history spans 8 years, with the latest figure at $2.9 million for Q1 2026.

  • Quarterly Leases fell 27.58% to $2.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2026, down 27.58% year-over-year, with the annual reading at $3.2 million for FY2025, 25.41% down from the prior year.
  • Leases came in at $2.9 million for Q1 2026, down from $3.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.0 million in Q1 2022 to a low of $2.9 million in Q1 2026.
  • The 5-year median for Leases is $5.0 million (2024), against an average of $5.0 million.
  • Year-over-year, Leases decreased 11.99% in 2022 and then dropped 27.58% in 2026.
  • Protara Therapeutics' Leases stood at $6.3 million in 2022, then dropped by 16.14% to $5.3 million in 2023, then decreased by 19.17% to $4.3 million in 2024, then decreased by 25.41% to $3.2 million in 2025, then decreased by 8.92% to $2.9 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Leases are $2.9 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025).